Chiasma Company Profile (NASDAQ:CHMA)

About Chiasma (NASDAQ:CHMA)

Chiasma logoChiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CHMA
  • CUSIP: N/A
  • Web:
  • Market Cap: $36.54 million
  • Outstanding Shares: 24,359,000
Average Prices:
  • 50 Day Moving Avg: $1.56
  • 200 Day Moving Avg: $1.79
  • 52 Week Range: $1.45 - $3.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.06
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.26 per share
  • Price / Book: 0.46
  • EBIDTA: ($42,610,000.00)
  • Return on Equity: -51.99%
  • Return on Assets: -46.38%
  • Current Ratio: 11.80%
  • Quick Ratio: 11.80%
  • Average Volume: 56,130 shs.
  • Beta: 1.72
  • Short Ratio: 16.91

Frequently Asked Questions for Chiasma (NASDAQ:CHMA)

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) announced its earnings results on Friday, May, 5th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.06. View Chiasma's Earnings History.

Who are some of Chiasma's key competitors?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:

  • David M. Stack, Independent Chairman of the Board
  • Mark J. Fitzpatrick, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
  • Drew Enamait, Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller
  • Roni Mamluk Ph.D., Chief Development Officer
  • Todd Foley, Independent Director
  • Bard J. Geesaman M.D. Ph.D., Independent Director
  • Scott Minick, Independent Director
  • John A. Scarlett M.D., Independent Director
  • John F. Thero CPA, Independent Director

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Who owns Chiasma stock?

Chiasma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (13.09%), Vanguard Group Inc. (1.31%) and Morgan Stanley (0.53%). View Institutional Ownership Trends for Chiasma.

Who bought Chiasma stock? Who is buying Chiasma stock?

Chiasma's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Morgan Stanley. View Insider Buying and Selling for Chiasma.

How do I buy Chiasma stock?

Shares of Chiasma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of Chiasma stock can currently be purchased for approximately $1.50.

MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
Community Ranking:  2.0 out of 5 ( )
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chiasma (NASDAQ:CHMA) (?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A

Analysts' Ratings History for Chiasma (NASDAQ:CHMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/17/2017Barclays PLCDowngradeEqual Weight -> UnderweightN/AView Rating Details
5/13/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
4/18/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$43.00 -> $9.00N/AView Rating Details
4/18/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Chiasma (NASDAQ:CHMA)
Earnings by Quarter for Chiasma (NASDAQ:CHMA)
Earnings History by Quarter for Chiasma (NASDAQ:CHMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.23)($0.29)ViewN/AView Earnings Details
8/10/2016Q2($0.63)($0.83)ViewListenView Earnings Details
5/11/2016Q1($0.63)($0.71)ViewListenView Earnings Details
3/14/2016Q4($0.53)($0.61)ViewListenView Earnings Details
11/12/2015Q315($0.38)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Chiasma (NASDAQ:CHMA)
Current Year EPS Consensus Estimate: $-0.90 EPS
Next Year EPS Consensus Estimate: $-1.42 EPS


Dividend History for Chiasma (NASDAQ:CHMA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Chiasma (NASDAQ:CHMA)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 58.35%
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2015Health Ventures Lp 7-MedMajor ShareholderBuy93,750$16.00$1,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Chiasma (NASDAQ:CHMA)
Latest Headlines for Chiasma (NASDAQ:CHMA)
DateHeadline logoChiasma Inc (CHMA) Issues Earnings Results - May 8 at 3:36 PM logoChiasma Reports First Quarter 2017 Results - May 5 at 4:30 PM logoChiasma reports 1Q loss - May 5 at 4:30 PM logoChiasma (CHMA) Receiving Somewhat Positive Media Coverage, Analysis Shows - April 29 at 2:03 PM logoChiasma (CHMA) Earns Daily Media Sentiment Score of 0.13 - April 25 at 12:40 PM logoChiasma (CHMA) Receives Daily Media Sentiment Rating of 0.42 - April 21 at 2:13 PM logoChiasma (CHMA) Earning Somewhat Critical News Coverage, Report Finds - April 15 at 11:21 AM logoShort Interest in Chiasma Inc (CHMA) Drops By 3.0% - April 11 at 7:13 AM logo Analysts Set $2.50 Target Price for Chiasma Inc (CHMA) - April 4 at 12:46 AM logoChiasma (CHMA) Announces Poster Presentation at ENDO - - March 31 at 2:43 AM logoChiasma (CHMA) Announces Poster Presentation at ENDO - March 30 at 9:43 PM logoChiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire - March 30 at 4:43 PM logoCHIASMA, INC Financials - March 22 at 3:34 PM logoChiasma Reports Fourth Quarter and Year End 2016 Results - March 16 at 10:37 PM logoCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 16 at 10:37 PM logoChiasma to Present at the Cowen and Company 37th Annual Health Care Conference - March 1 at 11:29 AM logoChiasma downgraded by Barclays - January 17 at 5:04 PM logoChiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017 - January 9 at 5:25 PM logo8:14 am Chiasma reviews 2016, provides preliminary outlook for 2017 - January 9 at 5:25 PM logoCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an - January 9 at 5:25 PM logoChiasma (CHMA) Shares March Higher, Can It Continue? - January 6 at 4:41 PM logo3:16 pm Chiasma: FDA states that Octreotide capsules are misbranded; requests Chiasma submit written response letter by January 6 - December 27 at 4:33 PM



Chiasma (CHMA) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff